Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879461 | 1.00 | FKBP1A (0.48) | FKBP1AAGTR2SIGMAR1S1PR5L3MBTL1 | |
| SCHEMBL124103 | 0.88 | L3MBTL1 (0.55) | SIGMAR1L3MBTL1POLB | |
| SCHEMBL6487168 | 0.87 | FKBP1A (0.55) | FKBP1AS1PR5L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2858521 | 0.87 | L3MBTL1 (0.54) | SIGMAR1L3MBTL1POLB | |
| SCHEMBL3120175 | 0.85 | SIGMAR1 (0.54) | FKBP1AAGTR2SIGMAR1 | |
| SCHEMBL2770293 | 0.83 | FKBP1A (0.55) | FKBP1APOLBSPHK1 | |
| SCHEMBL8343227 | 0.83 | AGTR2 (0.61) | AGTR2SIGMAR1S1PR5 | |
| SCHEMBL8409861 | 0.83 | AGTR2 (0.61) | AGTR2SIGMAR1S1PR5 | |
| SCHEMBL2864891 | 0.83 | AGTR2 (0.61) | AGTR2SIGMAR1S1PR5 | |
| SCHEMBL22620870 | 0.83 | S1PR5 (0.47) | SIGMAR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139652-B | ROR-gamma modulators | 爱思凯利尔生物科学私人有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | FKBP1A 3162/4885AGTR2 3553/4885SIGMAR1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.